We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$105M
Cap. Flow %
-2.67%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20
Avg Time Held Equity + Options
7 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
7.1 quarters
Top 10 Avg Time Held Equity only
7.2 quarters
Top 20 Avg Time Held Equity only
9.1 quarters

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO icon
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC icon
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Miscellaneous 0.71%
5 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SE icon
51
Sea Limited
SE
$58.3B
$6.96M 0.18%
97,500
-140,000
-59% -$9.25M
2022 Q1
9 quarters
PDD icon
52
Pinduoduo
PDD
$116B
$6.05M 0.15%
45,500
-11,000
-19% -$1.49M
2023 Q4
2 quarters
NVDA icon
53
NVIDIA
NVDA
$5.54T
$5.31M 0.14%
43,000
+24,000
+126% +$2.43M
2024 Q1
1 quarter
MSFT icon
54
Microsoft
MSFT
$3.97T
$5.05M 0.13%
11,300
+8,800
+352% +$3.72M
2023 Q2
4 quarters
V icon
55
Visa
V
$724B
$4.99M 0.13%
19,000
+16,500
+660% +$4.52M
2023 Q2
4 quarters
BDTX icon
56
Black Diamond Therapeutics
BDTX
$105M
$4.88M 0.12%
1,046,517
– –
2020 Q1
17 quarters
DT icon
57
Dynatrace
DT
$18.4B
$4.88M 0.12%
109,000
+73,000
+203% +$3.36M
2024 Q1
1 quarter
KLRS icon
58
Kalaris Therapeutics
KLRS
$56.2M
$4.77M 0.12%
286,833
– –
2020 Q3
15 quarters
APLT icon
59
DELISTED
Applied Therapeutics
APLT
$4.71M 0.12%
1,009,500
– –
2024 Q1
1 quarter
TSM icon
60
TSMC
TSM
$2.35T
$4.52M 0.12%
26,000
-6,000
-19% -$910K
2023 Q1
5 quarters
FHTX icon
61
Foghorn Therapeutics
FHTX
$119M
$4.14M 0.11%
720,720
– –
2020 Q4
14 quarters
DDOG icon
62
Datadog
DDOG
$105B
$3.75M 0.1%
28,925
+19,325
+201% +$2.34M
2023 Q2
4 quarters
ANRO icon
63
Alto Neuroscience
ANRO
$956M
$3.74M 0.1%
350,000
– –
2024 Q1
1 quarter
AMZN icon
64
Amazon
AMZN
$2.83T
$3.72M 0.09%
19,250
+7,250
+60% +$1.33M
2023 Q2
4 quarters
FATE icon
65
Fate Therapeutics
FATE
$261M
$3.39M 0.09%
1,032,500
+672,189
+187% +$2.94M
2024 Q1
1 quarter
HOOK icon
66
DELISTED
HOOKIPA Pharma
HOOK
$3.35M 0.09%
566,641
– –
2019 Q2
20 quarters
ADCT icon
67
ADC Therapeutics
ADCT
$221M
$3.22M 0.08%
+1,018,461
New +$4.05M
2024 Q2
0 quarters
BEKE icon
68
KE Holdings
BEKE
$19.6B
$3.18M 0.08%
225,000
-50,000
-18% -$783K
2022 Q4
6 quarters
RGNX icon
69
Regenxbio
RGNX
$533M
$2.92M 0.07%
250,000
– –
2024 Q1
1 quarter
OMGA icon
70
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$2.74M 0.07%
1,323,530
– –
2021 Q3
11 quarters
ELEV icon
71
DELISTED
Elevation Oncology
ELEV
$2.74M 0.07%
1,013,015
-500,000
-33% -$1.88M
2024 Q1
1 quarter
KVUE icon
72
Kenvue
KVUE
$34B
$2.49M 0.06%
+137,000
New +$2.65M
2024 Q2
0 quarters
SGMT icon
73
Sagimet Biosciences
SGMT
$633M
$2.48M 0.06%
724,771
– –
2023 Q3
3 quarters
CBIO icon
74
Crescent Biopharma
CBIO
$554M
$2.42M 0.06%
85,891
– –
2023 Q1
5 quarters
PCOR icon
75
Procore
PCOR
$8.54B
$2.14M 0.05%
32,300
+22,800
+240% +$1.58M
2023 Q2
4 quarters
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group's Q2 2024 filing shows 21 new, 29 increased, 29 reduced and 20 closed positions. Its largest new stake was Cullinan Oncology: 1,057,949 shares worth $18.5M. The largest sale was CAVA Group, an estimated $232M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.